Delamanid: A new armor in combating drug-resistant tuberculosis

被引：102
|
作者：
Xavier, Alphienes Stanley [1 ]
Lakshmanan, Mageshwaran [1 ]
机构：
[1] Jawaharlal Inst Postgrad Med Educ & Res, Dept Pharmacol, Pondicherry 605006, India
来源：
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS | 2014年 / 5卷 / 03期
关键词：
Delamanid; multidrug-resistant tuberculosis; mycolic acid inhibitor;
D O I：
10.4103/0976-500X.136121
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug-drug interactions and better tolerability.
引用
收藏
页码：222 / 224
页数：3
相关论文
共 50 条
  • [1] Delamanid for Extensively Drug-Resistant Tuberculosis
    Gupta, Rajesh
    Geiter, Lawrence J.
    Wells, Charles D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03): : 291 - 292
  • [2] The role of delamanid in the treatment of drug-resistant tuberculosis
    Lewis, Joseph M.
    Sloan, Derek J.
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 779 - 791
  • [3] Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis
    Mohr, Erika
    Ferlazzo, Gabriella
    Hewison, Cathy
    De Azevedo, Virginia
    Isaakidis, Petros
    [J]. LANCET INFECTIOUS DISEASES, 2019, 19 (05): : 470 - 470
  • [4] New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
    Brigden, Grania
    Hewison, Cathy
    Varaine, Francis
    [J]. INFECTION AND DRUG RESISTANCE, 2015, 8 : 367 - 378
  • [5] Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective
    Guglielmetti, Lorenzo
    Chiesi, Sheila
    Eimer, Johannes
    Dominguez, Jose
    Masini, Tiziana
    Varaine, Francis
    Veziris, Nicolas
    Ader, Florence
    Robert, Jerome
    [J]. FUTURE MICROBIOLOGY, 2020, 15 (09) : 779 - 799
  • [6] Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
    Marwah, Vikas
    Patil, Prashant R.
    Choudhary, Robin
    Malik, Virender
    [J]. LUNG INDIA, 2023, 40 (01) : 75 - 78
  • [7] Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline
    Furin, Jennifer
    Diacon, Andreas H.
    Andries, Koen
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2017, 21 (01) : 4 - 5
  • [8] Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review
    Pontali, Emanuele
    Sotgiu, Giovanni
    Tiberi, Simon
    Tadolini, Marina
    Visca, Dina
    D'Ambrosio, Lia
    Centis, Rosella
    Spanevello, Antonio
    Migliori, Giovanni Battista
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (01)
  • [9] First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
    Tadolini, Marina
    Lingtsang, Rangjung Dolma
    Tiberi, Simon
    Enwerem, Martin
    D'Ambrosio, Lia
    Sadutshang, Tsetan Dorji
    Centis, Rosella
    Migliori, Giovanni Battista
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2016, 48 (03) : 935 - 938
  • [10] Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
    Pecora, Francesco
    Dal Canto, Giulia
    Veronese, Piero
    Esposito, Susanna
    [J]. MICROORGANISMS, 2021, 9 (05)
12345